Lunit Inc. is a pioneering brand setting new milestones for AI in cancer care. Their AI technology has been adopted by over 2000 healthcare institutions globally, making a major impact in the fight against cancer.

Lunit's innovative products include the recently launched 3D breast screening product, <Lunit INSIGHT DBT>, and the Guardant360 TissueNext PD-L1 test powered by <Lunit SCOPE PD-L1>. The brand has received FDA clearance and CE mark approval for various products, solidifying its position as a leader in the field of medical imaging. Lunit's vision of saving lives through technology is reflected in their logo, symbolizing the connection of deep learning technology and the basic unit of life.

The company has been featured in publications such as Newsweek, FierceBiotech, Forbes, and MIT Tech Review, and has garnered recognition from organizations such as the World Economic Forum and the World Health Organization. With a focus on conquering cancer through AI, Lunit is paving the way for a healthier future for humankind